Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|February 5, 2024

Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

Experts underscore cost relief of bispecific antibodies via medication assistance programs.

Episodes in this series

Video 1 - "Conditions for Administering Bispecific Therapy"

EP. 1 Conditions for Administering Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 2 Navigating Barriers Which Inhibit Optimal Use of Bispecifics

Video 3 - "Key Decision Makers and Contributors Involved In Bispecific Administration"

EP. 3 Key Decision Makers and Contributors Involved In Bispecific Administration

Video 4 - "Pain Points In Bispecific Operationalization"

EP. 4 Pain Points In Bispecific Operationalization

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 5 Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 6 Optimizing Bispecific Use Through EMR Utilization

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 7 Best Practices For Uptake and Use of Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 8 Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 9 Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 10 Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 11 Protocol For Urgent and Around-the-Clock Bispecific Care

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 12 Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 13 Managed Care Considerations Within Bispecific Landscape

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 14 Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 15 Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 16 Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Health Equity & Access Weekly Roundup: June 26, 2026